NCT04818983

The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

The Exploratory Study to Evaluate Biomarkers in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer (J-TAIL-2)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 470 (actual)
• Sponsor: Chugai Pharmaceutical · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study ID: UMIN000041263, to evaluate biomarkers for selection of appropriate patients in treatment with atezolizumab combination therapy.

Conditions

• Non-small Cell Lung Cancer
• Extensive Disease Small Cell Lung Cancer

Timeline

• Start date: 2021-04-07
• Primary completion: 2023-02-03
• Completion: 2023-02-03
• First posted: 2021-03-26
• Last updated: 2024-04-02

Locations

95 sites across 1 country: Japan